Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Minnesota
With
National Institute on Drug Abuse (NIDA)
Subjects will be stratified by sex and then randomly assigned to active progesterone (PRO) or placebo (PBO).
Telephone screening and visit invitation leads to the consent process and in-person screening including medical-psychiatric evaluation for inclusion/exclusion, then randomization and medication induction, stable medication with medication reduction and final evaluation for secondary outcomes.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male 18 to 60 years old
Female 18 to 50 years old
Self-report regular smoking
Motivated to quit smoking
In stable physical/mental health
Self report of regular menstrual cycles (female only)
English fluency
Understand the study procedures and able to provide informed consent
Ability to participate fully in research elements for the duration of the trial.
You may not be if
Current or recent (\< 3 months) breastfeeding (females only)
Current or planned pregnancy within the next three months (females only)
Conditions contraindicated to progesterone treatment.